About this trial
Last updated 2 years ago
Study ID
STIMEX - 29BRC21.0025
Status
Recruiting
Type
Observational
Placebo
No
Accepting
18 to 99 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 4 years ago
What is this trial about?
The aim of this study is to determine the expression of STIM1 in the plasma membrane of
lymphocytes from patients suffering from different autoimmune diseases in order to identify
new pathologies of interest presenting an over-expression of STIM1PM.
This would allow to initiate, following this study, research and development programs on the
use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.
What are the participation requirements?
Inclusion Criteria
- Diagnosis of one of the autoimmune diseases
Exclusion Criteria
- Treatment with rituximab in the previous 12 months